251 related articles for article (PubMed ID: 30253201)
1. Utilizing microphysiological systems and induced pluripotent stem cells for disease modeling: a case study for blood brain barrier research in a pharmaceutical setting.
Fabre KM; Delsing L; Hicks R; Colclough N; Crowther DC; Ewart L
Adv Drug Deliv Rev; 2019 Feb; 140():129-135. PubMed ID: 30253201
[TBL] [Abstract][Full Text] [Related]
2. Fitting tissue chips and microphysiological systems into the grand scheme of medicine, biology, pharmacology, and toxicology.
Watson DE; Hunziker R; Wikswo JP
Exp Biol Med (Maywood); 2017 Oct; 242(16):1559-1572. PubMed ID: 29065799
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in human iPSC-derived models of the blood-brain barrier.
Workman MJ; Svendsen CN
Fluids Barriers CNS; 2020 Apr; 17(1):30. PubMed ID: 32321511
[TBL] [Abstract][Full Text] [Related]
4. Microphysiological Systems (Tissue Chips) and their Utility for Rare Disease Research.
Low LA; Tagle DA
Adv Exp Med Biol; 2017; 1031():405-415. PubMed ID: 29214585
[TBL] [Abstract][Full Text] [Related]
5. Blood-Brain Barrier and Neurodegenerative Diseases-Modeling with iPSC-Derived Brain Cells.
Wu YC; Sonninen TM; Peltonen S; Koistinaho J; Lehtonen Š
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299328
[TBL] [Abstract][Full Text] [Related]
6. Best Practices for Translational Disease Modeling Using Human iPSC-Derived Neurons.
Engle SJ; Blaha L; Kleiman RJ
Neuron; 2018 Nov; 100(4):783-797. PubMed ID: 30465765
[TBL] [Abstract][Full Text] [Related]
7. Establishment of a Human iPSC- and Nanofiber-Based Microphysiological Blood-Brain Barrier System.
Qi D; Wu S; Lin H; Kuss MA; Lei Y; Krasnoslobodtsev A; Ahmed S; Zhang C; Kim HJ; Jiang P; Duan B
ACS Appl Mater Interfaces; 2018 Jul; 10(26):21825-21835. PubMed ID: 29897225
[TBL] [Abstract][Full Text] [Related]
8. Introduction to a manuscript series on the characterization and use of microphysiological systems (MPS) in pharmaceutical safety and ADME applications.
Fabre K; Berridge B; Proctor WR; Ralston S; Will Y; Baran SW; Yoder G; Van Vleet TR
Lab Chip; 2020 Mar; 20(6):1049-1057. PubMed ID: 32073020
[TBL] [Abstract][Full Text] [Related]
9. A new era of disease modeling and drug discovery using induced pluripotent stem cells.
Suh W
Arch Pharm Res; 2017 Jan; 40(1):1-12. PubMed ID: 27921262
[TBL] [Abstract][Full Text] [Related]
10. Human pluripotent stem cells as tools for neurodegenerative and neurodevelopmental disease modeling and drug discovery.
Corti S; Faravelli I; Cardano M; Conti L
Expert Opin Drug Discov; 2015 Jun; 10(6):615-29. PubMed ID: 25891144
[TBL] [Abstract][Full Text] [Related]
11. Microphysiological Systems: A Pathologist's Perspective.
Sura R; Van Vleet T; Berridge BR
Vet Pathol; 2020 May; 57(3):358-368. PubMed ID: 32180532
[TBL] [Abstract][Full Text] [Related]
12. A Human Stem Cell-Derived Brain-Liver Chip for Assessing Blood-Brain-Barrier Permeation of Pharmaceutical Drugs.
Koenig L; Ramme AP; Faust D; Mayer M; Flötke T; Gerhartl A; Brachner A; Neuhaus W; Appelt-Menzel A; Metzger M; Marx U; Dehne EM
Cells; 2022 Oct; 11(20):. PubMed ID: 36291161
[TBL] [Abstract][Full Text] [Related]
13. Microphysiological systems in early stage drug development: Perspectives on current applications and future impact.
Kopec AK; Yokokawa R; Khan N; Horii I; Finley JE; Bono CP; Donovan C; Roy J; Harney J; Burdick AD; Jessen B; Lu S; Collinge M; Sadeghian RB; Derzi M; Tomlinson L; Burkhardt JE
J Toxicol Sci; 2021; 46(3):99-114. PubMed ID: 33642521
[TBL] [Abstract][Full Text] [Related]
14. The role of mutations associated with familial neurodegenerative disorders on blood-brain barrier function in an iPSC model.
Katt ME; Mayo LN; Ellis SE; Mahairaki V; Rothstein JD; Cheng L; Searson PC
Fluids Barriers CNS; 2019 Jul; 16(1):20. PubMed ID: 31303172
[TBL] [Abstract][Full Text] [Related]
15. Microphysiological systems meet hiPSC technology - New tools for disease modeling of liver infections in basic research and drug development.
Raasch M; Fritsche E; Kurtz A; Bauer M; Mosig AS
Adv Drug Deliv Rev; 2019 Feb; 140():51-67. PubMed ID: 29908880
[TBL] [Abstract][Full Text] [Related]
16. Cryopreservation of Brain Endothelial Cells Derived from Human Induced Pluripotent Stem Cells Is Enhanced by Rho-Associated Coiled Coil-Containing Kinase Inhibition.
Wilson HK; Faubion MG; Hjortness MK; Palecek SP; Shusta EV
Tissue Eng Part C Methods; 2016 Dec; 22(12):1085-1094. PubMed ID: 27846787
[TBL] [Abstract][Full Text] [Related]
17. Improved Ocular Tissue Models and Eye-On-A-Chip Technologies Will Facilitate Ophthalmic Drug Development.
Wright CB; Becker SM; Low LA; Tagle DA; Sieving PA
J Ocul Pharmacol Ther; 2020; 36(1):25-29. PubMed ID: 31166829
[TBL] [Abstract][Full Text] [Related]
18. Drug discovery using induced pluripotent stem cell models of neurodegenerative and ocular diseases.
Hung SSC; Khan S; Lo CY; Hewitt AW; Wong RCB
Pharmacol Ther; 2017 Sep; 177():32-43. PubMed ID: 28223228
[TBL] [Abstract][Full Text] [Related]
19. Microphysiological Systems: Stakeholder Challenges to Adoption in Drug Development.
Hargrove-Grimes P; Low LA; Tagle DA
Cells Tissues Organs; 2022; 211(3):269-281. PubMed ID: 34380142
[TBL] [Abstract][Full Text] [Related]
20. [Development of Microphysiological Systems (MPSs) Based on Microfluidic Technology for Drug Discovery in Japan].
Kimura H
Yakugaku Zasshi; 2023; 143(1):39-44. PubMed ID: 36596538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
